CliffBio
small molecule

KABIVEN IN PLASTIC CONTAINER

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL

Loss of exclusivityMay 2036latest FDA-listed patent expiry
CompanyFresenius Kabi →View the full company profile on CliffBio

Drug detail

Brand nameKABIVEN IN PLASTIC CONTAINER
Active ingredientAMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL
Strength3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (1540ML)
Dosage formEMULSION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalAugust 2014
Marketing statusRX

Listed patents

PatentExpiresType
12390398May 2036product

More from Fresenius Kabi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

KABIVEN IN PLASTIC CONTAINER patent cliff — loss of exclusivity May 2036 | CliffBio